[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370664-105":59,"doc-detail-370664-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","generation-of-two-induced-pluripotent-stem-cell-lines-from-breast-cancer-patients-carrying-brca1-mutations","Generation of Two Induced Pluripotent Stem Cell Lines from Breast Cancer Patients Carrying BRCA1 Mutations","","BRCA1 haploinsufficiency elevates cancer risk through essential roles in cell-cycle checkpoint regulation and DNA repair. The study generated and characterized two induced pluripotent stem cell (iPSC) lines derived from breast cancer patients carrying BRCA1 heterozygous mutations (c.676del and c.5096G>A). Both iPSC lines showed typical iPSC morphology, normal karyotype, pluripotency marker expression, and the ability to differentiate into three germ layers. BRCA1-mutated iPSCs provide a valuable platform for probing pathogenic mechanisms and supporting personalized medicine approaches.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/generation-of-two-induced-pluripotent-stem-cell-lines-from-breast-cancer-patients-carrying-brca1-mutations/370664/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/generation-of-two-induced-pluripotent-stem-cell-lines-from-breast-cancer-patients-carrying-brca1-mutations/370664.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Which BRCA1 mutations are used to generate the two iPSC lines?","Question",{"text":112,"@type":113},"The two lines were generated from patients carrying BRCA1 mutations c.676del and c.5096G>A.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What quality and characterization features do the generated iPSC lines show?",{"text":117,"@type":113},"Both lines exhibit typical iPSC morphology, karyotype, pluripotency marker expression, and trilineage differentiation capability.",{"name":119,"@type":110,"acceptedAnswer":120},"How are the BRCA1-mutated iPSC lines intended to be used?",{"text":121,"@type":113},"They are presented as a resource for investigating BRCA1-associated pathogenic mechanisms and for supporting drug screening and personalized medicine research.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370664,1790244707,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Stem Cell Res. Author manuscript; available in PMC 2025 August 01. |\n| --- | --- |\n\nPublished in final edited form as:  \nStem Cell Res. 2025 August ; 86: 103716. doi:10.1016/j.scr.2025.103716 .  \nGeneration of two induced pluripotent stem cell lines from breast cancer patients carrying BRCA1 mutations  \nYi-Ing Chena,b, Arianne Caudala,b, Amira G. Flores-Banuelosa,b, Christopher D. Yanc, Walter G. Parkd, Mohan Viswanathana,b, Joseph C. Wua,b,*  \naStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA  \nb Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA  \ncGreenstone Biosciences, Palo Alto, CA 94305, USA  \nd Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, CA 94305, USA  \nAbstract  \nHaploinsufficiency of BRCA1 increases the risk of various cancers due to its critical functions in cell cycle checkpoint regulation and DNA repair. This study generated and characterized two induced pluripotent stem cell (iPSC) lines derived from breast cancer patients with mutations in the BRCA1 gene (c.676del and c.5096G>A) . Both lines exhibited typical iPSC morphology, karyotype, pluripotency marker expression, and trilineage differentiation capabilities. BRCA1-mutated iPSCs provide a valuable resource to investigate pathogenic mechanisms and develop personalized medicine.  \n1. Resource table  \nUnique stem cell lines identifier Alternative name(s) of stem cell lines Institution  \n1. SCVIi135-A  \n2. SCVIi136-A  \n1. SCVI3161 (SCVIi135-A)  \n2. SCVI3171 (SCVIi136-A) Stanford Cardiovascular Institute  \nThis is an open access article under the CC BY-NC-ND license ([https://creativecommons.org/licenses/by-nc-nd/4.0/](https://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*Corresponding author at: 265 Campus Drive, G1120B, Stanford, CA 94305, [USA. joewu@stanford.edu](USA. joewu@stanford.edu) (J.C. Wu) . Declaration of competing interest  \nThe authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Joseph C. Wu reports a relationship with Greenstone Biosciences that includes: co-founder and member of scientific advisory board. The other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.  \nCRediT authorship contribution statement  \nYi-Ing Chen: Writing – original draft, Formal analysis, Data curation. Arianne Caudal: Writing – review & editing. Amira G. Flores-Banuelos: Resources. Christopher D. Yan: Resources. Walter G. Park: Writing – review & editing, Resources. Mohan  \nViswanathan: Resources. Joseph C. Wu: Writing – review & editing, Supervision, Conceptualization.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nChen et al. Page 2  \nContact information of distributor Type of cell lines  \nOrigin  \nAdditional origin info required for human ESC or iPSC  \nCell Source Clonality  \nMethod of reprogramming Genetic Modification  \nType of Genetic Modification  \nEvidence of the reprogramming transgene loss (including genomic copy if applicable)  \nAssociated disease Gene/locus  \nDate archived/stock date Cell line repository/bank Ethical approval  \nJoseph C. Wu, [joewu@stanford.edu](joewu@stanford.edu)[ ](joewu@stanford.edu)iPSCs  \nHuman  \nAge: 51 (SCVIi135-A); 82 (SCVIi136-A)  \nSex: Female (both lines)  \nEthnicity if known: Caucasian (both lines) PBMC  \nClonal  \nSendai virus vectors expressing Oct4, Sox2, Klf4, and c-Myc YES  \nSpontaneous mutation RT-qPCR  \nBreast cancer (both lines)  \nBRCA1 (17q21.31)  \nSCVIi135-A: BRCA1 c.676del (p. Cys226fs)  \nSCVIi136-A: BRCA1 c.5096G>A (p. Arg1699Gln)  \nSCVIi135-A: 3/15/2024  \nSCVIi136-A: 4/8/2024  \n[https://hpscreg.eu/cell-line/SCVIi135-A](https://hp","cbCaiaEUIgNBuZu1","https://ap.wps.com/l/cbCaiaEUIgNBuZu1","pdf",1164097,"English","# Abstract\n# 1. Resource table\n## Unique stem cell lines identifiers\n# 2. Resource utility\n# 3. Resource details","[{\"question\":\"Which BRCA1 mutations are used to generate the two iPSC lines?\",\"answer\":\"The two lines were generated from patients carrying BRCA1 mutations c.676del and c.5096G\\u003eA.\"},{\"question\":\"What quality and characterization features do the generated iPSC lines show?\",\"answer\":\"Both lines exhibit typical iPSC morphology, karyotype, pluripotency marker expression, and trilineage differentiation capability.\"},{\"question\":\"How are the BRCA1-mutated iPSC lines intended to be used?\",\"answer\":\"They are presented as a resource for investigating BRCA1-associated pathogenic mechanisms and for supporting drug screening and personalized medicine research.\"}]","Generation of Two Induced Pluripotent Stem Cell Lines from Breast Cancer Patients Carrying BRCA1 Mutations | PDF",1790189689,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dbd9ddc6a6ba590084c59f4e48c9fe1.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1622d493a585230e8d09d769d2b8486a.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d8c32c87dccb8c712e7e1e6852aabc75.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/68522ca01393e4dbebd48411a68084c9.webp",980,1268]